Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104


Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease.

Letzen JE, Lanzkron S, Bond K, Carroll CP, Haythornthwaite JA, Nance S, Campbell CM.

Pain Rep. 2019 Mar 22;4(2):e724. doi: 10.1097/PR9.0000000000000724. eCollection 2019 Mar-Apr.


Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities.

Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA.

J Clin Transl Sci. 2018 Oct;2(5):334-342. doi: 10.1017/cts.2018.338. Review.


Overcoming challenges of venous thromboembolism in sickle cell disease treatment.

Ogunsile FJ, Naik R, Lanzkron S.

Expert Rev Hematol. 2019 Mar;12(3):173-182. doi: 10.1080/17474086.2019.1583554. Epub 2019 Mar 8.


Metabolic syndrome among adults living with sickle cell disease.

Ogunsile FJ, Bediako SM, Nelson J, Cichowitz C, Yu T, Patrick Carroll C, Stewart K, Naik R, Haywood C Jr, Lanzkron S.

Blood Cells Mol Dis. 2019 Feb;74:25-29. doi: 10.1016/j.bcmd.2018.10.005. Epub 2018 Oct 22.


Correction to: Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record.

Goddu AP, O'Conor KJ, Lanzkron S, Saheed MO, Saha S, Peek ME, Haywood C Jr, Beach MC.

J Gen Intern Med. 2019 Jan;34(1):164. doi: 10.1007/s11606-018-4583-7.


Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy.

Duan XJ, Lanzkron S, Linz MO, Ewing C, Wang J, Scott AW.

Am J Ophthalmol. 2019 Jan;197:105-113. doi: 10.1016/j.ajo.2018.09.025. Epub 2018 Sep 29.


Increased acute care utilization in a prospective cohort of adults with sickle cell disease.

Lanzkron S, Little J, Field J, Shows JR, Wang H, Seufert R, Brooks J, Varadhan R, Haywood C Jr, Saheed M, Huang CY, Griffin B, Frymark S, Piehet A, Robertson D, Proudford M, Kincaid A, Green C, Burgess L, Wallace M, Segal J.

Blood Adv. 2018 Sep 25;2(18):2412-2417. doi: 10.1182/bloodadvances.2018018382.


Risks associated with fertility preservation for women with sickle cell anemia.

Pecker LH, Maher JY, Law JY, Beach MC, Lanzkron S, Christianson MS.

Fertil Steril. 2018 Sep;110(4):720-731. doi: 10.1016/j.fertnstert.2018.05.016.


Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease.

Ter-Minassian M, Lanzkron S, Derus A, Brown E, Horberg MA.

J Natl Med Assoc. 2019 Feb;111(1):54-61. doi: 10.1016/j.jnma.2018.05.003. Epub 2018 Jun 22.


Challenges in the management of the transgender patient with sickle cell disease.

Ronda J, Nord A, Arrington-Sanders R, Naik R, Takemoto CM, Baskin J, Lanzkron S, Pecker LH.

Am J Hematol. 2018 Nov;93(11):E360-E362. doi: 10.1002/ajh.25242. Epub 2018 Oct 12. No abstract available.


A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis.

Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM, Moliterno AM, Brodsky RA.

Medicine (Baltimore). 2018 Aug;97(31):e11579. doi: 10.1097/MD.0000000000011579.


Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of non-hematologic characteristics and baseline chronic opioid dose.

Carroll CP, Cichowitz C, Yu T, Olagbaju YO, Nelson JA, Campbell T, Lanzkron S.

Am J Hematol. 2018 Sep;93(9):1127-1135. doi: 10.1002/ajh.25168. Epub 2018 Aug 15.


A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971.


Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record.

P Goddu A, O'Conor KJ, Lanzkron S, Saheed MO, Saha S, Peek ME, Haywood C Jr, Beach MC.

J Gen Intern Med. 2018 May;33(5):685-691. doi: 10.1007/s11606-017-4289-2. Epub 2018 Jan 26. Erratum in: J Gen Intern Med. 2019 Jan;34(1):164.


Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis.

Finan PH, Carroll CP, Moscou-Jackson G, Martel MO, Campbell CM, Pressman A, Smyth JM, Tremblay JM, Lanzkron SM, Haythornthwaite JA.

J Pain. 2018 Jan;19(1):46-56. doi: 10.1016/j.jpain.2017.08.010. Epub 2017 Sep 21.


Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.

Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, McHutchison JG, Sulkowski M.

Clin Infect Dis. 2017 Sep 1;65(5):864-866. doi: 10.1093/cid/cix441.


Look into my eyes: An unusual first presentation of sickle cell disease.

Sood R, Jiramongkolchai K, Streiff M, Gonzalez C, Shanbhag S, Lanzkron S, Arevalo JF, Naik R.

Am J Hematol. 2017 Sep;92(9):968-971. doi: 10.1002/ajh.24787. Epub 2017 Jun 9. No abstract available.


Negative studies shape the state of sickle trait.

Lanzkron S, Naik RP.

Blood. 2017 Feb 9;129(6):661-662. doi: 10.1182/blood-2016-12-753400. No abstract available.


Examination of the Patient and Hospitalization Characteristics of 30-Day SCD Readmissions.

Carroll CP, Haywood C Jr, Lanzkron SM.

South Med J. 2016 Sep;109(9):583-7. doi: 10.14423/SMJ.0000000000000526.


Effect of Free Dental Services on Individuals with Sickle Cell Disease.

Whiteman LN, Haywood C Jr, Lanzkron S, Strouse JJ, Batchelor AH, Schwartz A, Stewart RW.

South Med J. 2016 Sep;109(9):576-8. doi: 10.14423/SMJ.0000000000000510.

Supplemental Content

Loading ...
Support Center